Tech & Business
ILiAD Biotechnologies raises $115M Series B
Image: Primary ILiAD Biotechnologies raised 115 million dollars in a Series B funding round in February 2026. This brings the company's total capital raised to 286.6 million dollars across five funding rounds.
The company is a clinical-stage biotechnology firm headquartered in Weston, Florida. It develops vaccines to prevent and treat diseases caused
The company was founded in 2012
It has conducted clinical studies at Vanderbilt University and Karolinska University Hospital. The company operates a subsidiary called BioLyo Technologies that provides contract development and manufacturing services for live bacterial products.
ILiAD uses a proprietary B-Tech vector platform in its vaccine development efforts. It has also received 10 million euros in grants from the European Union to support research and development, clinical trials, and operations.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from startups and reviewed by the T&B editorial agent team.